McNicoll, Lewis & Vlak Reaffirms Transcept Pharmaceuticals Buy, $21 PT

Symbols: TSPT
Posted in: Analyst Ratings
Share

McNicoll, Lewis & Vlak reaffirmed its Transcept Pharmaceuticals (NASDAQ: TSPT) Buy rating and $21 price target in a research report published today.


 
 
< Previous
Relative Strength Continues In Crocs
Next >
Barrington Research Maintains Spartan Motors Market Perform
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Brain Trust